4.7 Review

Current and Future Development in Lung Cancer Diagnosis

期刊

出版社

MDPI
DOI: 10.3390/ijms22168661

关键词

lung cancer; diagnosis; imaging; biomarkers; predictors; body fluids

资金

  1. MITACS grant [IT22349]
  2. BioMark Diagnostics Inc. (Richmond, BC, Canada)

向作者/读者索取更多资源

Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries, emphasizing the importance of early diagnosis. Current diagnostic methods have limitations and necessitate the search for new biomarkers to improve early detection rates.
Lung cancer is the leading cause of cancer-related deaths in North America and other developed countries. One of the reasons lung cancer is at the top of the list is that it is often not diagnosed until the cancer is at an advanced stage. Thus, the earliest diagnosis of lung cancer is crucial, especially in screening high-risk populations, such as smokers, exposure to fumes, oil fields, toxic occupational places, etc. Based on the current knowledge, it looks that there is an urgent need to identify novel biomarkers. The current diagnosis of lung cancer includes different types of imaging complemented with pathological assessment of biopsies, but these techniques can still not detect early lung cancer developments. In this review, we described the advantages and disadvantages of current methods used in diagnosing lung cancer, and we provide an analysis of the potential use of body fluids as carriers of biomarkers as predictors of cancer development and progression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据